ICDx develops breakthrough immunocomplex antibody technology that enables faster, more accurate, and cost-effective hormone testing for clinical laboratories and point-of-care applications.
ICDx is a next-generation hormone testing platform based on novel high-affinity immunocomplex antibodies.
This technology enables a faster, more accurate, and cost-effective alternative to conventional diagnostic methods.
The ICDx project is developing a novel assay technology that delivers unprecedented sensitivity and robustness for hormone detection.
Currently in the research and developing stage at the University of Turku – funded by Business Finland.
© 2025 ICDx | Next-Generation Hormone Diagnostics | University of Turku. Created for free using WordPress and Kubio